Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Retained Earnings (2020 - 2025)

Apellis Pharmaceuticals has reported Retained Earnings over the past 6 years, most recently at -$2.1 million for Q4 2025.

  • Quarterly results put Retained Earnings at -$2.1 million for Q4 2025, up 36.43% from a year ago — trailing twelve months through Dec 2025 was -$2.1 million (up 36.43% YoY), and the annual figure for FY2025 was -$2.1 million, up 36.43%.
  • Retained Earnings for Q4 2025 was -$2.1 million at Apellis Pharmaceuticals, up from -$2.4 million in the prior quarter.
  • Over the last five years, Retained Earnings for APLS hit a ceiling of -$875000.0 in Q4 2022 and a floor of -$3.0 billion in Q3 2024.
  • Median Retained Earnings over the past 5 years was -$1.4 billion (2021), compared with a mean of -$1.3 billion.
  • Biggest five-year swings in Retained Earnings: soared 99.95% in 2022 and later crashed 324184.34% in 2023.
  • Apellis Pharmaceuticals' Retained Earnings stood at -$1.7 billion in 2021, then soared by 99.95% to -$875000.0 in 2022, then crashed by 324184.34% to -$2.8 billion in 2023, then surged by 99.88% to -$3.3 million in 2024, then soared by 36.43% to -$2.1 million in 2025.
  • The last three reported values for Retained Earnings were -$2.1 million (Q4 2025), -$2.4 million (Q3 2025), and -$2.6 million (Q2 2025) per Business Quant data.